VEEVA SYSTEMS INC (VEEV)
SEC filings, insider trading & institutional ownership from EDGAR.
Veeva Systems Inc. is a provider of industry cloud solutions for the global life sciences industry, spanning cloud software, data, and business consulting. Its offerings are designed to help life sciences companies develop and bring products to market faster, market and sell more effectively, and maintain compliance with government regulations, from research and development through commercialization. Veeva is a Delaware public benefit corporation, with a stated purpose of providing products and services that help make the industries it serves more productive and creating high-quality employment opportunities in the communities where it operates.
The solutions are grouped into four product categories. Veeva Development Cloud covers clinical, regulatory, and safety functions, including clinical data management and operations (EDC, CDB, eTMF, CTMS, RTSM), Veeva Safety, and Veeva RIM, all built on the Veeva Vault platform. Veeva Quality Cloud includes Veeva QMS, Quality Docs, lab, and training solutions. Veeva Commercial Cloud includes Vault CRM and the legacy Veeva CRM, Veeva Medical, PromoMats, and Crossix marketing analytics. Veeva Data Cloud includes OpenData, Veeva Link, Compass, and HCP Access. Veeva AI adds agentic AI agents to Vault and its applications. For financial reporting, Commercial Solutions combines Commercial Cloud and Data Cloud, while R&D and Quality Solutions combines Development Cloud and Quality Cloud. Veeva also provides professional services (implementation, managed services, data migration, training) and Veeva Consulting for commercial and R&D strategy.
As of January 31, 2026, Veeva served 1,552 customers, including pharmaceutical, biotechnology, and medical device companies, contract sales organizations, and contract research organizations. These range from large global companies such as Bayer, Eli Lilly, Gilead, Merck, and Novartis to emerging biotechs such as Alkermes and Alnylam. Some Development and Quality Cloud applications are also sold to consumer products companies and others outside life sciences. Veeva sells through a direct sales organization with separate R&D and quality and commercial teams, further divided between large global and smaller life sciences companies.
Veeva had 7,928 employees as of January 31, 2026. Its products are hosted in third-party data centers in the United States, European Union, Japan, South Korea, Singapore, Australia, Brazil, and China. Vault applications run on Amazon Web Services, while Veeva CRM runs on Salesforce infrastructure, and its AI Agents use large language models from Anthropic and Amazon. Its technology is generally multitenant, and it maintains an ISO 9001 quality management system and a data privacy program. Competitors include Salesforce in CRM, IQVIA, Ipsos, and Definitive Health in data, and IQVIA, Dassault Systèmes, OpenText, Oracle, and Honeywell in development and quality applications. Veeva relies on patents, trade secrets, copyrights, and trademarks, with 111 issued U.S. patents and 164 pending applications.
AI-summarized from Item 1 (Business) of the company’s most recent 10-K filing.
Financials
As reported to the SEC via XBRL, no adjustments
| Gross profit | $2.41B |
| Operating income | $916.37M |
| Diluted EPS | $5.44 |
| Gross margin | 75.5% |
| Net margin | 28.4% |
Latest filings
10-K, 10-Q, 8-K, Form 4 & 13D/G. Sourced directly from SEC EDGAR
| Form | Filed | Accession |
|---|---|---|
| 8-K | Nov 6, 2026 | 0001393052-26-000039EDGAR |
| 4Ritter Gordon | Oct 19, 2026 | 0001628280-26-066333EDGAR |
| 4Faddis Jonathan | Oct 17, 2026 | 0001628280-26-066134EDGAR |
| 4Zuppas Eleni Nitsa | Oct 6, 2026 | 0001628280-26-065022EDGAR |
| 4Van Wagener Brian | Oct 6, 2026 | 0001628280-26-065019EDGAR |
| 4Schwenger Thomas D. | Oct 6, 2026 | 0001628280-26-065015EDGAR |
| 4Rizzo Daniel J | Oct 6, 2026 | 0001628280-26-065011EDGAR |
| 4Kondath Vipin | Oct 6, 2026 | 0001628280-26-065005EDGAR |
Insider trading
From Form 4 filings
| Insider | Date | Type |
|---|---|---|
| Ritter Gordon | Oct 15, 2026 | J |
| Ritter Gordon | Oct 15, 2026 | Acquire (J) |
| Faddis Jonathan | Oct 14, 2026 | Sell |
| Faddis Jonathan | Oct 2, 2026 | Gift |
| Rizzo Daniel J | Oct 2, 2026 | Sell |
Top holders
13F & 13D/G • latest quarter
| Holder | Stake | Filed | Value |
|---|---|---|---|
| BlackRock, Inc. | 7.9% | Aug 7, 2026 | $2.28B |
| Vanguard Capital Management | 6.0% | Aug 13, 2026 | $1.72B |
| Vanguard Portfolio Management | 4.6% | Aug 13, 2026 | $1.32B |
| GEODE CAPITAL MANAGEMENT, LLC | 2.8% | Nov 6, 2026 | $1.3B |
| STATE STREET CORPORATION | 4.1% | Sep 22, 2026 | $1.19B |
VEEV's filings are public. The insight is one click away.
Scrutar's AI reads every VEEV filing and points out what matters. Red flags, risk shifts, disclosure quality and key relationships. Cited to the source, free with an account.
Never miss a VEEV filing.
Get an email when VEEV files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Nov 8, 2026Source: SEC EDGAR.